Harvard College

Immunis.ai, Inc.

Other

Cell Mdx, LLC

Amin I Kassis

Harry Stylli

Colleen Kelly

Geoffrey Erickson

S James Adelstein

Kirk J Wojno

Ravi S Harapanhalli

Leslie A Khawli

Catherine F Foulon

Choukrie Akili-Mudarris

Janina Baranowska-Kortylewicz

Kirk J Wonjo

The invention described herein provides biological markers for the diagnosis, prognosis, and monitoring of prostate cancer.

Methods of detecting prostate cancer

The invention described herein provides biological markers for the diagnosis, prognosis, and monitoring of prostate cancer

This invention provides a set of biological markers that are useful for detecting cancer. This invention further provides methods of using those biological markers for the diagnosis, prognosis, or monitoring of cancer.

Methods of detecting cancer

This invention provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of autoimmune or immune-related diseases or conditions. The invention also provides methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of autoimmune or immune-related diseases or conditions.

Methods of detecting autoimmune or immune-related diseases or conditions

Methods and compositions for diagnosing the presence of a cancer cell in an individual are provided. Methods and compositions for identifying a tumor-specific signature in an individual having cancer are also provided. Methods and compositions for diagnosing the presence of an infectious agent in an individual and/or for identifying an infectious agent-specific signature in an infected individual are provided. Methods and compositions for diagnosing the presence of a disease in an individual are also provided. Methods and compositions for identifying a disease-specific signature in an individual having the disease are also provided.

Methods of detecting signatures of disease or conditions in bodily fluids

This invention provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of prenatal or pregnancy-related diseases or conditions. The invention also provides methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of prenatal or pregnancy-related diseases or conditions.

Methods of detecting prenatal or pregnancy-related diseases or conditions

Kits and methods provide for the isolation of white blood cells from bodily fluids. In one exemplary aspect, a method for isolating white blood cells from blood includes the act of adding a blood sample to a separation tube having a distal end, a proximal end, and a valve located proximate said proximal end, said valve being configured to transition between at least first, second, and third positions. The method also includes the act of removably attaching a cap to the distal end, centrifuging the separation tube with the valve in the first position, removing the cap at the distal end of the separation tube and removably attaching a first syringe to the proximal end, switching the valve to the second position and withdrawing, via the first syringe, a red blood cell sediment. The method also includes the act of switching the valve to the first position and removing the first syringe, adding a small volume of buffer to the separation tube, removably attaching a cap to the distal end and centrifuging the separation tube and removing the cap at the distal end of the separation tube and removably attaching a second syringe to the proximal end. Additional acts include switching the valve to the second position, withdrawing the remaining red blood cell sediment via the second syringe and switching the valve to the first position and removing the second syringe.

Methods and apparatus for isolation of white blood cells using a multiposition valve

The invention provides methods and compositions, e.g., for tumor imaging and therapy.

Compounds and methods for enzyme-mediated tumor imaging and therapy

The present invention discloses a method for the enzyme-mediated, site-specific, in-vivo precipitation of a water soluble molecule in an animal. The enzyme is either unique to tumor cells, or is produced within a specific site (e.g., tumor) at concentrations that are higher than that in normal tissues. Alternatively, the enzyme is conjugated to a targeting moiety such as an antibody or a receptor-binding molecule.

Growing community of inventors

Chestnut Hill, MA, United States of America

Amin I Kassis